Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer
KRAS G12C inhibitors such as sotorasib and adagrasib are often effective in KRAS G12C–driven non–small cell lung cancer (NSCLC) patients. However, acquired resistance limits long-term patient survival. In this issue of the JCI, Tsai et al. present a comprehensive genetic analysis of multiple tumors...
Main Authors: | Tadashi Manabe, Trever G. Bivona |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical Investigation
2022-02-01
|
Series: | The Journal of Clinical Investigation |
Online Access: | https://doi.org/10.1172/JCI156891 |
Similar Items
-
Unveiling the role of KRAS in tumor immune microenvironment
by: Miao Xu, et al.
Published: (2024-02-01) -
Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ
by: Yi Liu, et al.
Published: (2022-05-01) -
Mechanisms of Resistance to KRAS<sup>G12C</sup> Inhibitors
by: Victoria Dunnett-Kane, et al.
Published: (2021-01-01) -
Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
by: Marc Cucurull, et al.
Published: (2022-01-01) -
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
by: Dana S. Neel, et al.
Published: (2017-03-01)